Preferred Label : Betifisolimab;
NCIt synonyms : Anti-PDL1 Monoclonal Antibody MSB2311; Humanized Anti-PD-L1 Monoclonal Antibody MSB2311; Anti-PD-L1 Monoclonal Antibody MSB2311;
NCIt definition : A second-generation, humanized monoclonal antibody directed against the immunosuppressive
ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274),
with potential immune checkpoint inhibitory and antineoplastic activities. Betifisolimab
contains a unique, not as of yet elucidated, pH-dependent antigen binding property
allowing the antibody to only bind to PD-L1 within the acidic tumor microenvironment
(TME), while it is not able to bind to PD-L1 in normal, healthy tissue. Upon administration,
once able to bind to PD-L1 in the TME, betifisolimab blocks the binding of PD-L1 to
and activation of its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed
death-1). This reverses T-cell inactivation caused by PD-L1/PD-1 signaling, increases
T-cell expansion and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor
immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many
human cancer cell types. PD-L1 binding to PD-1 on activated T-cells suppresses the
immune system and results in immune evasion. PD-1 negatively regulates T-cell activation.;
UNII : V7XRB4BO26;
CAS number : 2460539-60-8;
Molecule name : MSB 2311; MSB-2311;
NCI Metathesaurus CUI : CL562806;
Origin ID : C155931;
UMLS CUI : C5706643;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
